Crinetics Pharmaceuticals, Inc. Operating Lease, Right-of-Use Asset, Amortization Expense
Crinetics Pharmaceuticals, Inc. (CRNX) reported Operating Lease, Right-of-Use Asset, Amortization Expense of $1.39 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-03.
Financial Statements › Cash Flow › Operating Activities
us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense · last filed 2026-08-03
- Crinetics Pharmaceuticals, Inc. operating lease, right-of-use asset, amortization expense for the quarter ending 2026-06-30 was $683.00K, a 13.76% decline year-over-year.
- Crinetics Pharmaceuticals, Inc. operating lease, right-of-use asset, amortization expense for the quarter ending 2026-03-31 was $703.00K, a 13.53% decline year-over-year.
- Crinetics Pharmaceuticals, Inc. operating lease, right-of-use asset, amortization expense for the quarter ending 2025-12-31 was $654.00K, a 13.83% decline year-over-year.
- Crinetics Pharmaceuticals, Inc. operating lease, right-of-use asset, amortization expense for the quarter ending 2025-09-30 was $755.00K.
- Crinetics Pharmaceuticals, Inc. operating lease, right-of-use asset, amortization expense for fiscal 2025 was $3.01M, a 0.92% decline from fiscal 2024.
- Crinetics Pharmaceuticals, Inc. operating lease, right-of-use asset, amortization expense for fiscal 2024 was $3.04M, a 151.40% increase from fiscal 2023.
- Crinetics Pharmaceuticals, Inc. operating lease, right-of-use asset, amortization expense for fiscal 2023 was $1.21M.
| Period end | Operating Lease, Right-of-Use Asset, Amortization Expense 3 month | Operating Lease, Right-of-Use Asset, Amortization Expense 6 month | Operating Lease, Right-of-Use Asset, Amortization Expense 9 month | Operating Lease, Right-of-Use Asset, Amortization Expense 12 month |
|---|---|---|---|---|
| 2026-06-30 | $683.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-03 | $1.39M 10-Q · filed 2026-08-03 | $2.04M derived: sum of 3 quarters · filed 2026-08-03 | $2.79M derived: sum of 4 quarters · filed 2026-08-03 |
| 2026-03-31 | $703.00K 10-Q · filed 2026-05-07 | $1.36M derived: sum of 2 quarters · filed 2026-05-07 | $2.11M derived: sum of 3 quarters · filed 2026-05-07 | $2.90M derived: sum of 4 quarters · filed 2026-08-03 |
| 2025-12-31 | $654.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $1.41M derived: sum of 2 quarters · filed 2026-02-26 | $2.20M derived: sum of 3 quarters · filed 2026-08-03 | $3.01M 10-K · filed 2026-02-26 |
| 2025-09-30 | $755.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | $1.55M derived: sum of 2 quarters · filed 2026-08-03 | $2.36M 10-Q · filed 2025-11-06 | $3.12M derived: sum of 4 quarters · filed 2026-08-03 |
| 2025-06-30 | $792.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-03 | $1.60M 10-Q · filed 2026-08-03 | $2.36M derived: sum of 3 quarters · filed 2026-08-03 | |
| 2025-03-31 | $813.00K 10-Q · filed 2026-05-07 | $1.57M derived: sum of 2 quarters · filed 2026-05-07 | ||
| 2024-12-31 | $759.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $3.04M 10-K · filed 2026-02-26 | ||
| 2024-09-30 | $2.28M 10-Q · filed 2025-11-06 | |||
| 2023-12-31 | $1.21M 10-K · filed 2026-02-26 |